Cobimetinib Fumarate

US Brand Name(s) Cotellic

Use in Cancer Treatment

Cobimetinib fumarate has an authorization for its use with vemurafenib to treat the following conditions:

Experts cannot remove Melanoma surgically or which has spread (spread to other parts of the body). It’s main use is to treat cancer patients who have a mutation in the BRAF gene.

Researchers are also researching Cobimetinib fumarate for use in the treatment of various cancers.


An orally accessible small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1) with possible antineoplastic action in the fumarate salt. Cobimetinib binds to MEK1 and reduces its catalytic activity, resulting in phosphorylation and activation of extracellular signal-related kinase 2 (ERK2) and reduced tumor cell growth. This drug has been shown to be effective in suppressing the development of tumor cells with the B-RAF mutation, which has been linked to a variety of tumor types in preclinical investigations. MEK1 is a threonine-tyrosine kinase that is necessary for the transmission of growth-promoting signals from a variety of receptor tyrosine kinases. It is a major component of the RAS/RAF/MEK/ERK signaling pathway, which is commonly active in human malignancies.

Cobimetinib Fumarate – MedlinePlus Information – Warnings about this drug; what this drug is for and how to use it; what you should tell your doctor before using this drug; things you should know about this drug before using it; other drugs that may interact with this drug; and possible side effects are all examples of lay language summaries of important information about this drug.

Experts are frequently investigating drugs to see whether they can assist treat or prevent conditions other than those for which they have an authorization. This patient information leaflet only covers an authorized uses of the medications. Much of the material, though, might also apply to authorized uses that are being investigated.